ICER will assess the comparative clinical effectiveness and value of treatments for peanut allergy. The report is expected to focus on two therapies: Viaskin® Peanut (DBV Technologies), which is currently undergoing FDA review with an approval decision expected in mid-2019, and AR101 (Aimmune Therapeutics). Aimmune has announced its intention to submit a biologics license application with the FDA by the end of 2018 for AR101. This list is tentative and subject to change.
CTAF will convene to review ICER's assessment of treatments for peanut allergy.